ADMA ADMA Biologics Inc

4.13
-0.01  -0%
Previous Close 4.14
Open 4.13
Price To Book 6.77
Market Cap 244,984,806
Shares 59,318,355
Volume 17,418
Short Ratio
Av. Daily Volume 681,719
Stock charts supplied by TradingView

NewsSee all news

  1. ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  2. ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

    Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG) Off to an Encouraging Start RAMSEY, N.J. and BOCA RATON, Fla., Nov. 06, 2019 (GLOBE NEWSWIRE)

  3. ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 04, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  4. ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  5. ADMA Biologics Announces Data Presented at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced April 1, 2019.
RI-002
Primary Immune Deficiency Diseases
Response to Complete Response Letter submitted January 7, 2019.
BIVIGAM
Primary humoral immunodeficiency

Latest News

  1. ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  2. ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

    Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG) Off to an Encouraging Start RAMSEY, N.J. and BOCA RATON, Fla., Nov. 06, 2019 (GLOBE NEWSWIRE)

  3. ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 04, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  4. ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  5. ADMA Biologics Announces Data Presented at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

  6. ADMA Biologics Announces Poster Presentation at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 03, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

  7. ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

  8. ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin